Gazyva 1000mg injection contains the active substance Obinutuzumab. It is an antineoplastic drug that belongs to the class of medications called Anti-CD20 monoclonal antibodies. It is used in combination with other anticancer medicines to treat chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL)  in adults. It works by killing and stopping cancer cells from growing. 

Do not take this Gazyva 1000mg injection if you are allergic to obinutuzumab or any other ingredients of this medicine. Inform your physician if you have an active infection, or suffered from any infections, weak immune system, have or had heart problems, brain disorders, eye disorders, breathing problems, and liver diseases. Report to your physician if you face any symptoms of sudden difficulty in breathing, dizziness, diarrhoea, cough, skin rash, chest pain, or fever after the administration of the injection.  

Inform your physician if you face any symptoms of memory loss, trouble speaking, difficulty walking, or problems with your eyesight during the treatment with Gazyva 1000mg injection because these may indicate rare and life-threatening side effects. This medicine is not recommended for children and young people under 18 years of age. Use an effective method of contraception while being treated with this injection.   Avoid pregnancy and breastfeeding during the treatment. 

• Chronic lymphocytic leukemia (CLL)
• Non-Hodgkin’s lymphoma (NHL)

Chronic lymphocytic leukemia (CLL) and Non-Hodgkin’s lymphoma (NHL) are types of cancer that affect a specific type of WBC called B-lymphocytes. The affected cells multiply too quickly and survive longer. Gazyva 1000mg injection binds to CD20 targets on the surface of the affected B-lymphocyte cells and causes them to die. When the injection is administered to the patient with other anticancer medicines, this slows down the progression time of the disease and works effectively by killing the abnormal cancer cells. 

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, recent vaccinations, nutritional and vitamin supplements, and herbal products. Certain medications may interact with Gazyva 1000mg injection and reduce its effectiveness by causing undesirable side effects. 

• Store Gazyva 1000mg injection in the refrigerator (2°C to 8°C)
• Do not freeze
• keep the injection away from the reach of children and pets.
• If you have missed any dosing appointments, inform your doctor and schedule immediately.

It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors. Your doctor will give you certain medications to lessen the chance of getting side effects from the Gazyva 1000mg injection treatment.  

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. 

Common 

• Hair fall
• Constipation, diarrhea
• Anemia
• Decreased WBC and platelets
• Infection
• Muscle pain
• Headache, insomnia
• Urinary tract infections
• Cough
• Fever, tiredness
• Decreased appetite

Serious 

• Bleeding in the stomach
• Anemia
• Hypersensitivity reactions
• Brain problems
• Severe infections

Gazyva 1000mg injection may interfere with vaccines, inform your physician before taking any flu shot or any other vaccines. This injection may cause severe birth defects if taken during pregnancy. Female patients with reproductive potential should use effective contraception during the treatment. Do not breastfeed during treatment and for 6 months after your last dose. Inform your doctor if you have a history of hepatitis B infection. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury. Wash your hands often. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy. 

1. Gazyvaro 1,000 mg concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [Revised 2022] [cited 2023 Apr 25]. Available from: https://www.medicines.org.uk/emc/product/3279/pil
2. GAZYVA-obinutuzumab injection. [revised on 2017] [cited 2023 Apr 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf
3. Jenny O’Nions, William Townsend et al; The role of obinutuzumab in the management of follicular lymphoma; Future Oncology; Published on Nov 2019; Accessed on 25/04/2023; https://pubmed.ncbi.nlm.nih.gov/31538821/